Dronedarone

證據等級: L5

預測適應症: 10 個

Dronedarone: From Atrial Fibrillation/Flutter to Stroke

One-Sentence Summary

Dronedarone is a Class III antiarrhythmic used to control heart rhythm in atrial fibrillation/flutter (AF/AFL). The TxGNN model predicts it may also reduce stroke risk, and this direction is already supported by 19 clinical trials and 20 publications — including both a positive pivotal signal (ATHENA) and a critical negative safety signal (PALLAS) that must bound any use case.

Quick Overview

Item	Content
Original Indication	Atrial Fibrillation / Atrial Flutter (AF/AFL) — extracted from evidence-pack literature; TFDA license data is unavailable because the drug is not marketed in Taiwan
Predicted New Indication	Stroke Disorder
TxGNN Prediction Score	99.97%
Evidence Level	L2
Taiwan Market Status	未上市 (Not Marketed)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed formal MOA data for dronedarone is not available in DrugBank per this evidence pack (data gap DG002). Based on information embedded in the evidence base itself, dronedarone is a multi-ion-channel-blocking Class III antiarrhythmic, structurally related to but non-iodinated compared with amiodarone. It was developed for rhythm/rate control in AF/AFL, and there is mechanistic evidence that it also exerts direct anticoagulant and antiplatelet effects independent of its antiarrhythmic action (PMID 28992468).

The link between AF/AFL and stroke is well established: AF is a major driver of cardioembolic stroke, and effective rhythm control that reduces AF burden can lower thromboembolic risk. The pivotal ATHENA trial (summarized in PMID 20730068) showed dronedarone reduced cardiovascular hospitalization/death in paroxysmal or persistent AF, with a post-hoc signal of reduced stroke risk — this is the mechanistic basis for the TxGNN prediction.

Critically, this relationship is not unconditional. The PALLAS trial (NCT01151137, PMID 22082198), conducted specifically in permanent AF patients, was terminated early because dronedarone increased stroke, MI, and cardiovascular death. So the evidence bifurcates by AF subtype: protective in paroxysmal/persistent AF, harmful in permanent AF. Any repurposing pathway must explicitly exclude permanent AF patients.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01151137	Phase 3	Terminated	3,236	PALLAS: dronedarone 400mg BID in permanent AF with additional risk factors — terminated early due to increased stroke, MI, and CV death; defines the contraindication boundary.
NCT01288352	Phase 4	Completed	2,789	EAST-AFNET4: early structured rhythm-control therapy (including dronedarone) vs usual care reduced AF-related cardiovascular complications, including stroke.
NCT00911508	N/A	Completed	2,204	CABANA: catheter ablation vs antiarrhythmic drug therapy (including dronedarone) for AF; indirect comparator evidence.
NCT01856075	N/A	Completed	1,015	Real-world observational study comparing dronedarone’s effectiveness vs other antiarrhythmics in AF (Germany, Spain, Italy, USA).
NCT05279833	N/A	Completed	87,810	Systematic literature review/NMA comparing dronedarone (Multaq) vs sotalol safety, including stroke outcomes, in AF.
NCT05130268	Phase 4	Completed	339	Pragmatic RCT of early dronedarone vs usual care in first-detected AF; supports an early rhythm-control strategy.
NCT05293080	Phase 3	Not yet recruiting	1,746	Tests whether early rhythm-control therapy prevents adverse cardiovascular outcomes in patients with acute ischemic stroke and AF.
NCT02618577	Phase 3	Terminated	2,608	NOAH-AFNET6: oral anticoagulation vs current therapy to prevent stroke/systemic embolism/CV death in atrial high-rate episodes — context trial for AF-stroke prevention strategy.
NCT01266681	N/A	Unknown	100	Amiodarone vs dronedarone for maintenance of sinus rhythm post-cardioversion in persistent AF; low certainty (status unknown).
NCT05939076	Phase 3	Not yet recruiting	220	Compares early cryoballoon ablation vs antiarrhythmic drug therapy (including dronedarone) in persistent AF.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
22082198	2011	RCT (PALLAS)	New England Journal of Medicine	Dronedarone in high-risk permanent AF increased major vascular events (stroke, MI, CV death); trial terminated early — key negative safety signal.
40387892	2025	RCT post-hoc (EAST-AFNET4)	Clinical Research in Cardiology	Long-term safety/efficacy of amiodarone and dronedarone for early rhythm control within EAST-AFNET4; reassuring long-term outcome data.
20730068	2010	Review (approval)	Vascular Health and Risk Management	Reviews dronedarone’s FDA approval based on the ATHENA trial (reduced CV hospitalization/death); post-hoc analysis suggested reduced stroke risk, but PALLAS later raised safety concerns in permanent AF.
28496906	2013	Cohort (safety)	Journal of Atrial Fibrillation	Real-world retrospective cohort comparing risk of stroke, CV events, CHF, and other adverse events between dronedarone, amiodarone, and other antiarrhythmics.
28992468	2017	Mechanistic	Atherosclerosis	Shows dronedarone exerts direct anticoagulant/antiplatelet effects independent of its antiarrhythmic action — a mechanistic explanation for ATHENA’s stroke/TIA reduction.
37485722	2023	Cohort (veterans)	Circulation: Arrhythmia and Electrophysiology	Retrospective comparison of dronedarone vs sotalol effectiveness/safety in AF patients within the VA healthcare system.
35293087	2022	Review/subgroup (ATHENA post-hoc)	European Journal of Heart Failure	Dronedarone’s cardiovascular risk reduction in AF/AFL patients with concomitant HFpEF/HFmrEF, a population with elevated stroke risk.
33888353	2021	Cohort (DDI)	Clinical Therapeutics	Real-world evaluation of digitalis intoxication risk with concomitant dronedarone + digoxin use — a relevant drug-interaction safety signal.
22166900	2012	Review	Lancet	General review of AF management, including stroke risk stratification and evolution of antithrombotic therapy.
22920480	2012	Review	Current Cardiology Reviews	Reviews stroke prevention concepts and controversies in AF, contextualizing rhythm-control agents such as dronedarone.

Safety Considerations

Please refer to the package insert for safety information.

(Note: formal DDI/warning/contraindication fields in this evidence pack are data gaps — TFDA label data has not yet been retrieved, flagged as blocking gap DG001. However, evidence-base rationale text does surface two safety signals worth carrying forward: dronedarone is contraindicated in permanent AF per the PALLAS trial, and is contraindicated in sick sinus syndrome/bradycardia due to known sinus node effects.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The paroxysmal/persistent-AF evidence line (ATHENA, EAST-AFNET4) supports a plausible stroke-risk-reduction effect at L2 evidence strength, but the PALLAS trial shows the opposite effect in permanent AF, and formal Taiwan safety/label data is entirely missing (drug not currently marketed, 0 NDAs). This combination — real signal, real contraindication boundary, and a blocking data gap — means the candidate should advance only under explicit guardrails, not as a straightforward “Go.”

To proceed, the following is needed:

TFDA package insert warnings/contraindications (DG001, blocking — required before any S1 safety assessment)
Formal DrugBank MOA record (DG002)
Confirmation of Taiwan import/market pathway, since the drug currently has 0 licenses and is not marketed
A completed DDI database query (current status: not_found)
An explicit protocol excluding permanent AF patients, consistent with the PALLAS safety signal
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.